ARVINAS, INC. (ARVN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$87.3M
Cash & Equivalents
$69.2M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$571M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | PHASE3 | Active Not Recruiting | 59 |
| NCT06206837 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | PHASE2 | Active Not Recruiting | 71 |
| NCT05463952 | A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic ... | PHASE1 | Active Not Recruiting | 6 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.